Kodiak Sciences Inc. 8-K

What Happened
Kodiak Sciences Inc. (KOD) announced on March 26, 2026 (filed on Form 8-K March 27, 2026) positive topline results from GLOW2, the company’s second Phase 3 study in diabetic retinopathy. The company reported that Zenkuda™ (tarcocimab tedromer) demonstrated superiority versus sham in the trial. Kodiak attached the March 26 press release as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release date: March 26, 2026; Form 8-K filed March 27, 2026 (Item 8.01 Other Events).
• Study: GLOW2 — Kodiak’s second Phase 3 study in diabetic retinopathy.
• Drug: Zenkuda™ (tarcocimab tedromer) — reported to be superior to sham in topline results.
• Exhibit: Press release included as Exhibit 99.1 in the 8-K filing.

Why It Matters
This announcement reports a clinical milestone for Kodiak’s Zenkuda program: positive topline Phase 3 results are a key development-stage outcome that the company has publicly disclosed. The Form 8-K does not include financial results or detailed data in the filing itself; the company provided the press release as the primary source of information. Investors should review the attached press release and await the company’s release of full data and any regulatory or commercialization updates for a complete view of the impact on Kodiak’s development timeline.